Comparative Pharmacology
Head-to-head clinical analysis: GEMCITABINE versus XELODA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GEMCITABINE versus XELODA.
GEMCITABINE vs XELODA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gemcitabine is a nucleoside analog (2',2'-difluorodeoxycytidine) that is phosphorylated intracellularly to active diphosphate (dFdCDP) and triphosphate (dFdCTP) metabolites. dFdCDP inhibits ribonucleotide reductase, reducing deoxynucleotide pools for DNA synthesis. dFdCTP competes with deoxycytidine triphosphate for incorporation into DNA, causing masked chain termination and inhibiting DNA polymerase and repair.
Prodrug of 5-fluorouracil (5-FU), inhibits thymidylate synthase, incorporates into RNA and DNA, leading to cell death.
1000-1250 mg/m² intravenously over 30 minutes on days 1 and 8 of a 21-day cycle.
Capecitabine 1250 mg/m2 orally twice daily for 2 weeks followed by a 1-week rest period, administered as 3-week cycles.
None Documented
None Documented
Clinical Note
moderateGemcitabine + Digoxin
"Gemcitabine may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateGemcitabine + Digitoxin
"Gemcitabine may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateGemcitabine + Deslanoside
"Gemcitabine may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateGemcitabine + Acetyldigitoxin
"Gemcitabine may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life for gemcitabine is 42-94 minutes (mean ~57 min) in plasma; for its metabolite dFdU, the half-life is 14-74 hours (mean ~40 h), which accumulates with repeated dosing and may contribute to prolonged systemic exposure.
Capecitabine: 0.65-0.85 h; 5'-DFCR: 0.9-1.1 h; 5'-DFUR: 0.75-1.0 h; 5-FU: 0.75-1.1 h. Terminal half-life of 5-FU is short, requiring continuous dosing for sustained exposure.
Primarily renal: ~92-98% of the dose excreted in urine, with <10% as unchanged gemcitabine and the majority as the inactive metabolite 2',2'-difluorodeoxyuridine (dFdU). Fecal excretion is minimal (<1%).
Renal (95.5% as metabolites; 26.1% as parent drug and metabolites, primarily 5'-DFCR, 5'-DFUR, and FBAL); fecal (< 3%)
Category D/X
Category C
Antimetabolite
Antimetabolite